Raymond Kaempfer Selected Research

Superantigens

1/2019	Staphylococcal and Streptococcal Superantigens Trigger B7/CD28 Costimulatory Receptor Engagement to Hyperinduce Inflammatory Cytokines.
11/2018	Bacterial Superantigen Toxins, CD28, and Drug Development.
1/2017	Bacterial superantigen toxins induce a lethal cytokine storm by enhancing B7-2/CD28 costimulatory receptor engagement, a critical immune checkpoint.
10/2016	Superantigens hyperinduce inflammatory cytokines by enhancing the B7-2/CD28 costimulatory receptor interaction.
8/2015	Correction: Binding of Superantigen Toxins into the CD28 Homodimer Interface Is Essential for Induction of Cytokine Genes That Mediate Lethal Shock.
9/2013	CD28: direct and critical receptor for superantigen toxins.
6/2013	A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.
9/2011	Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.
2/2004	Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide.
1/2004	Peptide antagonists of superantigen toxins.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raymond Kaempfer Research Topics

Disease

7	Septic Shock (Toxic Shock Syndrome) 01/2019 - 06/2002
7	Shock 08/2015 - 07/2002
5	Cytokine Release Syndrome 01/2019 - 09/2011
3	Sepsis (Septicemia) 11/2018 - 03/2015
3	Inflammation (Inflammations) 06/2014 - 06/2013
2	Gram-Negative Bacterial Infections 11/2018 - 03/2015
2	Infections 03/2015 - 06/2013
2	Soft Tissue Infections 06/2014 - 06/2013
1	Thalassemia 01/2019
1	Wound Infection (Wound Infections) 11/2018
1	Coinfection 03/2015
1	Peritonitis 03/2015
1	Wounds and Injuries (Trauma) 01/2014
1	Bacterial Infections (Bacterial Infection) 06/2013
1	Multiple Sclerosis 02/2006
1	Necrosis 11/2003
1	Virus Diseases (Viral Diseases) 11/2003
1	Vaccinia 01/2002

Drug/Important Bio-Agent (IBA)

12	SuperantigensIBA 01/2019 - 06/2002
11	CytokinesIBA 01/2019 - 06/2002
8	Peptides (Polypeptides)IBA 11/2018 - 07/2002
4	AB103IBA 03/2015 - 06/2013
3	Interferon-gamma (Interferon, gamma)IBA 02/2006 - 11/2003
2	Virulence Factors (Pathogenicity Factors)IBA 01/2019 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2019 - 11/2003
2	Proteins (Proteins, Gene)FDA Link 11/2018 - 06/2013
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2017 - 10/2016
2	Messenger RNA (mRNA)IBA 02/2006 - 01/2002
2	staphylococcal enterotoxin BIBA 01/2004 - 06/2002
2	Interleukin-2 (IL2)IBA 01/2004 - 06/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2004 - 11/2003
1	GlobinsIBA 01/2019
1	Pharmaceutical PreparationsIBA 06/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2014
1	Cyclin D1IBA 01/2014
1	ExotoxinsIBA 06/2013
1	Therapeutic UsesIBA 02/2006
1	Interferon-betaIBA 02/2006
1	AntigensIBA 02/2004
1	Immunoglobulin G (IgG)IBA 02/2004
1	Immunoglobulin M (IgM)IBA 02/2004
1	LigandsIBA 01/2004
1	Double-Stranded RNA (RNA, Double Stranded)IBA 11/2003
1	Phosphotransferases (Kinase)IBA 11/2003
1	Antiviral Agents (Antivirals)IBA 11/2003
1	eIF-2 Kinase (eIF 2 Kinase)IBA 11/2003
1	2-Aminopurine (2 Aminopurine)IBA 01/2002

Therapy/Procedure

1	Ligation 03/2015
1	Punctures 03/2015
1	Therapeutics 06/2014
1	Debridement 06/2014